<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02783690</url>
  </required_header>
  <id_info>
    <org_study_id>15-006137</org_study_id>
    <nct_id>NCT02783690</nct_id>
    <nct_alias>NCT03391453</nct_alias>
  </id_info>
  <brief_title>A Trial of 15 Fraction vs 25 Fraction Pencil Beam Scanning Proton Radiotherapy After Mastectomy in Patients Requiring Regional Nodal Irradiation</brief_title>
  <official_title>MC1631: A Randomized Trial of 15 Fraction vs 25 Fraction Pencil Beam Scanning Proton Radiotherapy After Mastectomy in Patients Requiring Regional Nodal Irradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial to determine the safety of 15 fraction vs 25 fraction&#xD;
      pencil beam scanning proton radiotherapy after mastectomy in patients requiring regional&#xD;
      nodal irradiation. Proton therapy is recognized as a standard option for the delivery of&#xD;
      radiotherapy for breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 18, 2016</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">October 4, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complication rate, defined as grade 3 or greater late adverse events and unplanned surgical intervention in patients who undergo mastectomy with reconstruction</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Adverse Events</measure>
    <time_frame>90 days post-RT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Adverse Events and Reconstruction Failure</measure>
    <time_frame>90 days post-RT and up to 5 years post-RT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - breast cancer outcomes</measure>
    <time_frame>up to 5 years post-RT</time_frame>
    <description>measured by cosmesis evaluation and the Breast Cancer Treatment Outcome Scale (BCTOS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmesis</measure>
    <time_frame>baseline, 2 years, and 5 years</time_frame>
    <description>measured by reviewing digital photographs and the 4 point (excellent, good, fair, poor) adaptation of the Harvard Cosmesis Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IBTR Incidence</measure>
    <time_frame>at 5 years post RT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Recurrence Incidence</measure>
    <time_frame>at 5 years post RT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival (DFS)</measure>
    <time_frame>at 5 years post RT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>at 5 years post RT</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Conventional Fractionation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>50.0 Gy (RBE) in 25 daily fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypofractionation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 Gy (RBE) in 15 daily fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionation</intervention_name>
    <description>40 Gy (RBE) in 15 daily fractions</description>
    <arm_group_label>Hypofractionation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Histologic confirmation of breast cancer resected by mastectomy with or without&#xD;
             immediate reconstruction and chest wall and regional nodal irradiation planned.&#xD;
&#xD;
          -  pStage T1-T4N0-N3M0 or ypStage T0-4N0-N3M0 Note: The axilla must be staged by sentinel&#xD;
             node biopsy alone, sentinel node biopsy followed by axillary node dissection, or&#xD;
             axillary lymph node dissection alone&#xD;
&#xD;
          -  ECOG Performance Status (PS) 0 to 2. (Appendix I).&#xD;
&#xD;
          -  Negative pregnancy test done ≤7 days prior to registration, for women of childbearing&#xD;
             potential only.&#xD;
&#xD;
          -  Radiotherapy must begin within 12 weeks of last surgery (breast or axilla) or last&#xD;
             chemotherapy.&#xD;
&#xD;
        Note: Breast implants and expanders allowed&#xD;
&#xD;
          -  Able to and provides IRB approved study specific written informed consent&#xD;
&#xD;
          -  Ability to complete questionnaire (s) by themselves or with assistance&#xD;
&#xD;
          -  Able to complete all mandatory tests listed in section 4.0&#xD;
&#xD;
          -  Willing to return to enrolling institution for follow-up (during the active monitoring&#xD;
             phase of the study)&#xD;
&#xD;
          -  Willing to provide tissue and blood samples for correlative research purposes.&#xD;
&#xD;
          -  Rochester and Arizona patients: Willing to sign consent onto the Mayo Clinic&#xD;
             Radiotherapy Patient Outcomes Registry and Biobanking study, IRB number 15-000136&#xD;
&#xD;
          -  Rochester patients: Willing to sign consent onto Evaluation of cardiac function in&#xD;
             patients undergoing proton beam or photon radiotherapy, IRB number 15-007443&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical contraindication to receipt of radiotherapy.&#xD;
&#xD;
          -  Severe active co-morbid systemic illnesses or other severe concurrent disease which,&#xD;
             in the judgment of the investigator, would make the patient inappropriate for entry&#xD;
             into this study or interfere significantly with the proper assessment of safety and&#xD;
             toxicity of the prescribed regimens.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements or providing informed consent.&#xD;
&#xD;
          -  Active systemic lupus or scleroderma.&#xD;
&#xD;
          -  Pregnancy or women of childbearing potential who are sexually active and not&#xD;
             willing/able to use medically acceptable forms of contraception&#xD;
&#xD;
          -  Prior receipt of ipsilateral breast or chest wall radiation that would result in&#xD;
             significant overlap of radiation therapy fields. Prior contralateral radiotherapy for&#xD;
             breast cancer is allowed.&#xD;
&#xD;
          -  Positive margins after definitive surgery&#xD;
&#xD;
          -  History of non-breast malignancies (except for in situ cancers treated only by local&#xD;
             excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior&#xD;
             study entry&#xD;
&#xD;
          -  Inflammatory breast cancer&#xD;
&#xD;
          -  Recurrent Breast Cancer&#xD;
&#xD;
          -  Boosts to the chest wall after mastectomy. Nodal boosts are allowed.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert W Mutter</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 19, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2016</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Robert Mutter</investigator_full_name>
    <investigator_title>Assistant Professor of Radiation Oncology</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

